16 results about "Telomerase reverse transcriptase" patented technology

Telomerase reverse transcriptase (TERT) expression enhancing compounds, and methods for using the same, are provided. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

The present invention provides a method for screening for a telomerase reverse transcriptase (TERT) phosphorylation inhibitor using TERT or a fragment thereof, and a TERT kinase.

The invention relates to the use of an antitumor vaccine composed of two nine-amino-acid peptides - the original, cryptic TERT572 (RLFFYRKSV, SEQ ID NO:1) expressed by tumor cells and its optimized variant TERT572Y (YLFFYRKSV, SEQ ID NO: 2), for the treatment of a tumor expressing telomerase reverse transcriptase (TERT) in an HLA-A*0201 patient with normal levels of gamma-glutamyl transferase (gGT) and / or lactate dehydrogenase (LDH).

Described herein are recombinant viral genomes comprising a nucleotide sequence encoding a telomerase reverse transcriptase (TERT) operably linked to a tissue-specific and / or organ-specific promoter. Aspects described herein may be used in the treatment of conditions associated with shortened telomere length, such as pulmonary fibrosis, myocardial infarction and conditions associated therewith.

Telomerase reverse transcriptase (TERT) expression enhancing compounds, and methods for using the same, are provided. In some embodiments, the compounds are azoles, such as such as pyrazoles, imidazoles, triazoles, tetrazoles, thiazoles, isothiazoles, oxazoles, and isoxazoles. In certain embodiments, the azole compound includes an acyl substituent which includes an amide, for example, an alkyl amide. Methods of interest include contacting cells with a TERT expression enhancing effective amount of compound to increase TERT expression in the cells. These compounds and methods find use in a variety of applications in which increased expression of telomerase reverse transcriptase is desired.

Provided are immortalized Potamochoerus porcus macrophage cells obtained by causing Potamochoerus porcus macrophages to express at least one protein selected from the group consisting of an SV40 large T antigen and a telomerase reverse transcriptase.

The disclosure relates to compositions and methods for the treatment of fibrotic diseases and disorders and / or liver diseases and disorders, with one or more synthetic messenger ribonucleic acids (mRNAs) encoding telomerase reverse transcriptase (TERT).

Provided is an immortalized macrophage of a Caprinae subfamily animal obtained by causing a macrophage of a Caprinae subfamily animal to express at least one protein selected from the group consisting of SV40 large T antigen and telomerase reverse transcriptase.

The present invention relates to a polypeptide for delaying telomere shortening and its application, and belongs to the field of biotechnology. The present invention provides a polypeptide for delaying telomere shortening, and the amino acid sequence of the polypeptide is shown in SEQ ID NO.1. Studies have shown that the polypeptide has high biological activity and can significantly slow down the cell aging process by delaying telomere shortening, increasing the expression level of telomerase reverse transcriptase, increasing the activity of telomerase, and inhibiting the expression level of β-galactosidase. In addition, the polypeptide is derived from the fermentation process of natural dairy products and has high safety and low risk of side effects. In addition, the polypeptide has a small molecular weight and is easily absorbed by the human body, which can improve the bioavailability of the drug. Therefore, the polypeptide has great application prospects in delaying telomere shortening, anti-aging, and the treatment of diseases related to telomere loss or dysfunction.

The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.

The inventions relate to compounds and compositions comprising connexin hemichannel modulators, inflammasome modulators, and / or pannexin channel modulators and their use for the treatment of certain diseases, disorders, defects and conditions, including for the treatment of cells and subjects that contain shortened telomeres or that are in need of or may benefit from telomere extension, telomerase activity and / or telomerase reverse transcriptase activity, as well as for the treatment of cells and subjects for telomere-related diseases and / or telomere -related medical conditions, including cell senescence and cognitive decline. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro, ex vivo or in vivo, and kits including the compounds or compositions and instructions for use.

The inventions relate to compounds and compositions and their use for the treatment of certain diseases, disorders, defects and conditions, including for the treatment of cells and subjects that contain shortened telomeres or that are in need of or may benefit from telomere extension, telomerase activity and / or telomerase reverse transcriptase activity, as well as for the treatment of cells and subjects for telomere-related diseases and / or telomere-related medical conditions, including cell senescence and cognitive decline. Also provided are methods of extending telomeres through the administration of the provided compounds and compositions to animal cells, either in vitro, ex vivo or in vivo, and kits including the compounds or compositions and instructions for use.

The invention provides compositions and methods useful for the treatment and prevention of conditions associated with short telomere length, particularly kidney fibrosis.

The invention discloses an immortalized bovine muscle-derived stem cell line as well as a construction method and application thereof, and belongs to the technical field of stem cells and biological cell lines. The bovine muscle-derived stem cell line is characterized in that telomerase reverse transcriptase (TERT) and cyclin dependent kinase (CDK) genes are overexpressed in a mode of lentivirus packaging and infection, a cell strain which is single in source and stably expresses a target gene is obtained through monoclonal screening, gene verification and functional verification, and the verification shows that the cell line overexpresses the CDK4 and TERT genes, so that the cell line can be used for preparing the bovine muscle-derived stem cell line with the stable expression of the target gene. The monoclonal cell strain can stably proliferate and maintain good differentiation characteristics. The immortalized bovine muscle-derived stem cell line is prepared, and a good seed cell resource is reserved for commercialized production of cultured meat.

Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising administering an inhibitor of TERT to the subject.

Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising administering an inhibitor of TERT to the subject.